Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Miho Kure"'
Autor:
Tomohiro Fujiwara, John Healey, Koichi Ogura, Aki Yoshida, Hiroya Kondo, Toshiaki Hata, Miho Kure, Hiroshi Tazawa, Eiji Nakata, Toshiyuki Kunisada, Toshiyoshi Fujiwara, Toshifumi Ozaki
Publikováno v:
Cancers, Vol 13, Iss 5, p 1086 (2021)
Sarcomas are complex tissues in which sarcoma cells maintain intricate interactions with their tumor microenvironment. Tumor-associated macrophages (TAMs) are a major component of tumor-infiltrating immune cells in the tumor microenvironment and have
Externí odkaz:
https://doaj.org/article/58e8f64a44b44950bb0ed37e9c3c1944
Autor:
Koichi Ogura, Toshiyuki Kunisada, Eiji Nakata, Hiroya Kondo, John H. Healey, Hiroshi Tazawa, Aki Yoshida, Toshifumi Ozaki, Toshiaki Hata, Toshiyoshi Fujiwara, Miho Kure, Tomohiro Fujiwara
Publikováno v:
Cancers
Cancers, Vol 13, Iss 1086, p 1086 (2021)
Cancers, Vol 13, Iss 1086, p 1086 (2021)
Simple Summary Recent studies have shown the pro-tumoral role of tumor-associated macrophages (TAMs) not only in major types of carcinomas but also in sarcomas. Several types of TAM-targeted drugs have been investigated under clinical trials, which m
Autor:
Yusuke Mochizuki, Joe Hasei, Toshifumi Ozaki, Hiroshi Tazawa, Miho Kure, Toshiyoshi Fujiwara, Hiroya Kondo, Toshiyuki Kunisada, Aki Yoshida, Shunsuke Kagawa, Kazuhisa Sugiu, Tadashi Komatsubara, Yasuo Urata, Koji Demiya
Publikováno v:
Cancer immunology, immunotherapy : CII. 70(5)
Immune checkpoint inhibitors including anti-programmed cell death 1 (PD-1) antibody have recently improved clinical outcome in certain cancer patients; however, osteosarcoma (OS) patients are refractory to PD-1 blockade. Oncolytic virotherapy has eme
Autor:
Miho Kure, Koji Demiya, Toshiyoshi Fujiwara, Yusuke Mochizuki, Joe Hasei, Toshifumi Ozaki, Hiroshi Tazawa, Yasuo Urata, Toshiyuki Kunisada
Publikováno v:
Cancer Research. 79:3231-3231
Background: Osteosarcoma (OS) is the most frequent primary malignant tumor of bone in children and adolescents. Although immune checkpoint inhibitor, anti-programmed death protein 1 (PD-1) antibody, has dramatically improved the clinical outcome in s